Trestle Holdings, Bostwick Laboratories align on telepathology

TriMed Staff | | Health Imaging | Screening
Trestle Holdings Inc. will provide its MedMicro telepathology technology to Bostwick Laboratories under a new working agreement.

Bostwick, based in Richmond, Va., specializes in the diagnosis of cancer in urologic organs, with a focus on prostate cancer. Trestle develops and markets digital imaging and telemedicine applications for the life science markets.

Trestle's MedMicro product will connect Bostwick's lab microscopes to the Internet, allowing healthcare providers to interactively view and navigate slides from any similarly configured location from around the world.

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.